The large proportion of cancer staff who have recently left the FDA to join industry may prompt a reexamination of the relationship between the agency and pharma. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
